Aegis assumed coverage on shares of MediWound Ltd. (NASDAQ:MDWD) in a report issued on Monday. The brokerage set a “buy” rating and a $11.00 price target on the biopharmaceutical company’s stock. Aegis’ price objective would indicate a potential upside of 109.52% from the company’s previous close.
A number of other equities research analysts have also recently commented on MDWD. Zacks Investment Research cut MediWound from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Wells Fargo & Co. began coverage on MediWound in a research note on Wednesday, August 17th. They issued an “outperform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $13.25.
Shares of MediWound (NASDAQ:MDWD) traded up 2.86% on Monday, hitting $5.40. The company had a trading volume of 17,690 shares. The company’s market capitalization is $118.10 million. MediWound has a 52 week low of $5.00 and a 52 week high of $10.47. The stock’s 50-day moving average is $6.15 and its 200 day moving average is $7.31.
MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). MediWound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The company earned $0.52 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same period last year, the business posted ($0.17) earnings per share. The firm’s revenue was up 420.0% compared to the same quarter last year. Equities analysts expect that MediWound will post ($0.99) EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. bought a new position in shares of MediWound during the third quarter valued at $116,000. Wells Fargo & Company MN bought a new position in shares of MediWound during the third quarter valued at $202,000. Citadel Advisors LLC boosted its position in shares of MediWound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 1,456 shares in the last quarter. United Services Automobile Association boosted its position in shares of MediWound by 1.3% in the third quarter. United Services Automobile Association now owns 125,080 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 1,640 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of MediWound by 91,055.5% in the third quarter. Morgan Stanley now owns 182,311 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 182,111 shares in the last quarter. Institutional investors own 27.27% of the company’s stock.